Skip to main content
Erschienen in: Wiener klinisches Magazin 6/2015

01.12.2015 | Hämatologie

Autologe Stammzelltransplantation bei Myelompatienten

Ansätze zur Verbesserung der Ergebnisse

verfasst von: OA Priv.-Doz. Dr. Niklas Zojer

Erschienen in: Wiener klinisches Magazin | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Mit moderner Induktionstherapie gefolgt von Hochdosistherapie und autologer Transplantation werden heute 5-Jahres-Überlebensraten von 50–60 % erreicht. Die Transplantation im Rahmen der Erstlinientherapie dürfte sich als Standard weiterhin behaupten. Eine Doppeltransplantation kann in Einzelfällen sinnvoll sein, etwa bei Patienten, die während der Induktion nicht zumindest eine VGPR erreichen oder bei Patienten mit 17p-Deletion. Mit Konsolidierungs- bzw. Erhaltungsstrategien lässt sich die Remission vertiefen bzw. die Zeit bis zur Progression verlängern.
Literatur
1.
Zurück zum Zitat Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N (2015) Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant 50(2):209–215CrossRefPubMed Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N (2015) Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant 50(2):209–215CrossRefPubMed
2.
Zurück zum Zitat Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31(26):3279–3287CrossRefPubMed Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31(26):3279–3287CrossRefPubMed
3.
Zurück zum Zitat Cavo M, Pantani L, Pezzi A, Cavallo F, Petrucci MT, Di Raimondo F, Patriarca F, Waage A, Zamagni E, Montefusco V, Galli M, Gamberi B, Rossi G, Tacchetti P, Grasso M, Zweegman S, Offidani M, Ballanti S, Zambello R, Liberati AM, Bassan R, Pregno P, Palumbo A, Sonneveld P (2014) superior efficacy of VTD over VCD as induction therapy for autotransplantation-eligible, newly diagnosed, myeloma patients. ASH 2014, abstract 197. ASH, San Francisco Cavo M, Pantani L, Pezzi A, Cavallo F, Petrucci MT, Di Raimondo F, Patriarca F, Waage A, Zamagni E, Montefusco V, Galli M, Gamberi B, Rossi G, Tacchetti P, Grasso M, Zweegman S, Offidani M, Ballanti S, Zambello R, Liberati AM, Bassan R, Pregno P, Palumbo A, Sonneveld P (2014) superior efficacy of VTD over VCD as induction therapy for autotransplantation-eligible, newly diagnosed, myeloma patients. ASH 2014, abstract 197. ASH, San Francisco
4.
Zurück zum Zitat Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29(8):1721–1729CrossRefPubMed Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29(8):1721–1729CrossRefPubMed
5.
Zurück zum Zitat Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375–4382CrossRefPubMed Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375–4382CrossRefPubMed
6.
Zurück zum Zitat Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL (2013) Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 31(2):247–255CrossRefPubMed Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL (2013) Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 31(2):247–255CrossRefPubMed
7.
Zurück zum Zitat Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, Oriol A, Hernández-Ruiz B, Rayón C, Navarro I, García-Ruiz JC, Besalduch J, Gardella S, López Jiménez J, Díaz-Mediavilla J, Alegre A, San Miguel J, Bladé J (2012) PETHEMA/Spanish Myeloma Group. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica 97(4):616–621PubMedCentralCrossRefPubMed Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, Oriol A, Hernández-Ruiz B, Rayón C, Navarro I, García-Ruiz JC, Besalduch J, Gardella S, López Jiménez J, Díaz-Mediavilla J, Alegre A, San Miguel J, Bladé J (2012) PETHEMA/Spanish Myeloma Group. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica 97(4):616–621PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R, InterGroupe Francophone du Myélome (IFM) (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495–2502CrossRefPubMed Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R, InterGroupe Francophone du Myélome (IFM) (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495–2502CrossRefPubMed
9.
Zurück zum Zitat Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895–905CrossRefPubMed Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895–905CrossRefPubMed
10.
Zurück zum Zitat Palumbo A, Gay F, Spencer A, Di Raimondo F, Zdenek A, Larocca A, Falcone AP, Catalano L, Finsinger P, Vlastimil S, Aschero S, Offidani M, Liberati AM, Carella AM, Vladimir M, Donato F, Caravita T, Corradini P, Ria R, Pulini S, Stocchi R, Conticello C, Petrucci MT, Hajek R, Boccadoro M (2013) A phase III study of aSCT vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone maintenance vs Lenalidomide alone in newly diagnosed myeloma patients. ASH 2013, abstract 763. ASH, New Orleans Palumbo A, Gay F, Spencer A, Di Raimondo F, Zdenek A, Larocca A, Falcone AP, Catalano L, Finsinger P, Vlastimil S, Aschero S, Offidani M, Liberati AM, Carella AM, Vladimir M, Donato F, Caravita T, Corradini P, Ria R, Pulini S, Stocchi R, Conticello C, Petrucci MT, Hajek R, Boccadoro M (2013) A phase III study of aSCT vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone maintenance vs Lenalidomide alone in newly diagnosed myeloma patients. ASH 2013, abstract 763. ASH, New Orleans
11.
Zurück zum Zitat Gay F, Cerrato C, Hajek R, Di Raimondo F, Caravita T, Falcone AP, Patriarca F, Pulini, Finsinger P, Ciccone G, Corradini P, Siniscalchi A, Donato F, Yehuda BD, Offidani M, Minarik J, Ria R, Cavallo F, Catalano L, Cavalli M, Pour L, Petrucci MT, Hardan I, Boccadoro M, Spencer A, Palumbo A (2014) Impact of Autologous transplantation vs. chemotherapy plus Lenalidomide in newly diagnosed myeloma according to patient prognosis: results of a pooled analysis of 2 phase III trials. ASH 2014, abstract 198. ASH, San Francisco Gay F, Cerrato C, Hajek R, Di Raimondo F, Caravita T, Falcone AP, Patriarca F, Pulini, Finsinger P, Ciccone G, Corradini P, Siniscalchi A, Donato F, Yehuda BD, Offidani M, Minarik J, Ria R, Cavallo F, Catalano L, Cavalli M, Pour L, Petrucci MT, Hardan I, Boccadoro M, Spencer A, Palumbo A (2014) Impact of Autologous transplantation vs. chemotherapy plus Lenalidomide in newly diagnosed myeloma according to patient prognosis: results of a pooled analysis of 2 phase III trials. ASH 2014, abstract 198. ASH, San Francisco
12.
Zurück zum Zitat Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084CrossRefPubMed Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084CrossRefPubMed
13.
Zurück zum Zitat Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Stoppa AM, Garciaz S, Touzeau C, Chaleteix C, Fermand JP, Loiseau HA, Facon T, Attal M, Moreau P, InterGroupe Francophone du Myélome (IFM) (2013) Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 27(11):2242–2244CrossRefPubMed Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Stoppa AM, Garciaz S, Touzeau C, Chaleteix C, Fermand JP, Loiseau HA, Facon T, Attal M, Moreau P, InterGroupe Francophone du Myélome (IFM) (2013) Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 27(11):2242–2244CrossRefPubMed
14.
Zurück zum Zitat Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF, Grupo Español de MM (2013) A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 27(10):2056–2061CrossRefPubMed Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF, Grupo Español de MM (2013) A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 27(10):2056–2061CrossRefPubMed
15.
Zurück zum Zitat Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 119(1):7–15CrossRefPubMed Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 119(1):7–15CrossRefPubMed
16.
Zurück zum Zitat Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P, Dutch-Belgian HOVON Group, German GMMG Group (2013) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121(4):624–627CrossRefPubMed Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P, Dutch-Belgian HOVON Group, German GMMG Group (2013) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121(4):624–627CrossRefPubMed
17.
Zurück zum Zitat Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL, IFM Investigators (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782–1791CrossRefPubMed Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL, IFM Investigators (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782–1791CrossRefPubMed
18.
Zurück zum Zitat McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 10;366(19):1770–1781 (May)CrossRef McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 10;366(19):1770–1781 (May)CrossRef
Metadaten
Titel
Autologe Stammzelltransplantation bei Myelompatienten
Ansätze zur Verbesserung der Ergebnisse
verfasst von
OA Priv.-Doz. Dr. Niklas Zojer
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 6/2015
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-015-0077-y

Weitere Artikel der Ausgabe 6/2015

Wiener klinisches Magazin 6/2015 Zur Ausgabe